Use of Flibanserin in the Treatment of Obesity

Abstract

The invention relates to a method for the treatment of obesity and related diseases comprising the administration of a therapeutically effective amount of Flibanserin.

1 . A method of inhibiting body weight gain comprising administering to an individual in need thereof a therapeutically effective amount of flibanserin, or a pharmacologically acceptable acid addition salt thereof. 
     
     
         2 . The method according to  claim 7 , comprising administering a second active ingredient comprising active substances for the treatment of diabetes; active substances for the treatment of diabetic complications; active substances for the treatment of obesity; active substances for the treatment of high blood pressure; active substances for the treatment of hyperlipidaemia, including arteriosclerosis; active substances for the treatment of dyslipidaemia, including arteriosclerosis; or active substances for the treatment of arthritis. 
     
     
         3 . The method according to  claim 7 , comprising administering a second active ingredient comprising orlistat, phenetermine, sibutramine, or topiramate, or a pharmaceutically acceptable salt thereof. 
     
     
         4 . The method according to  claim 7 , comprising administering a second active ingredient comprising ergoset, pramlintinide, leptin, BAY-27-9955, glipazide, glyburide, alprostadil, thipride hydrochloride, cilostazol, mexiletine hydrochloride, ethyl eicosapentate, memantine, or pimagedine, or a pharmaceutically acceptable salt thereof. 
     
     
         5 . The method according to  claim 7 , comprising administering a second active ingredient comprising an insulin sensitiser, insulin secretion accelerator, biguanide, insulin, α-glucosidase inhibitor, or β3 adrenoreceptor agonist, glycogen phosphorylase inhibitor, sorbitol dyhydrogenase inhibitor, protein tyrosine phosphatase 1B inhibitor, dipeptidyl protease inhibitor, aldose reductase inhibitor, glycation inhibitor, protein kinase C inhibitor, DPPIV blocker, GLP-1 or GLP-2 analogue, or SGLT-2 inhibitor, lipase inhibitor, anorectic, angiotensin converting enzyme inhibitor, calcium antagonist, potassium channel opener, angiotensin II antagonist, HMG-CoA reductase inhibitor, fibrate compound, or non-steroidal anti-inflammatory drug. 
     
     
         6 . The method according to  claim 7 , comprising administering a second active ingredient comprising pioglitazone or a pharmaceutically acceptable salt thereof, troglitazone, rosiglitazone or a pharmaceutically acceptable salt thereof, JTT-501, GI-262570, MCC-555, YM-440, DRF-2593, BM-13-1258, KRP-297, R-119702, GW-1929, tolbutamide, chloropropamide, tolazamide, acetohexamide, glyclopyramide, an ammonium salt of glyclopyramide, glibenclamide, gliclazide, glimepiride, repaglinide, nateglinide, mitiglinide, JTT-608, metformin, buformin, phenformin, bovine insulin, porcine insulin, semisynthetic human insulin, genetically-engineered human insulin, acarbose, voglibose, miglitol, emiglitate, AJ-9677, BMS-196085, SB-226552, AZ40140, tolrestat, epalrestat, imirestat, zenarestat, SNK-860, zopolrestat, ARI-50i, AS-3201, NGF, LY-333531, LAF237, MK431, 815541, 823093, 825964, liraglutide, exenatide, AVE-2268, T-1095, mazindol, baiamine, NGD-95-1, lipstatin, rimonabant, phenylpropanolamine, ephedrine, pseudroephedrine, dexfenfluramine, fenfluramine, BVT.933, APD356, bromocriptine, pramipexol, dehydroepiandrosterone, exendin, AC 2993, CJC-1131, ZP10, GRT0203Y, captopril, enalapril, alacepril, delapril, lisinopril, imidapril, benazepril, cilazapril, temocapril, trandolapril, manidipine, nifedipine, amlodipine, efonidipine, nicardipine, levcromakalim, L-27152, AL0671, NIP-121, telmisartan, losartan, candesartan cilexetil, valsartan, irbesartan, CS-866, E4177, pravastatin or a pharmaceutically acceptable salt thereof, simvastatin or a pharmaceutically acceptable salt thereof, lovastatin or a pharmaceutically acceptable salt thereof, atorvastatin or a pharmaceutically acceptable salt thereof, fluvastatin or a pharmaceutically acceptable salt thereof, lipantil or a pharmaceutically acceptable salt thereof, cerivastatin or a pharmaceutically acceptable salt thereof, itavastatin or a pharmaceutically acceptable salt thereof, ZD-4522 or a pharmaceutically acceptable salt thereof, bezafibrate, clinofibrate, clofibrate, simfibrate, meloxicam, ibuprofen, or mixtures thereof. 
     
     
         7 . A method of inhibiting or reducing appetite comprising administering to an individual in need thereof a therapeutically effective amount of flibanserin, or a pharmacologically acceptable acid addition salt thereof. 
     
     
         8 . The method according to claim  13 , comprising administering a second active ingredient comprising active substances for the treatment of diabetes; active substances for the treatment of diabetic complications; active substances for the treatment of obesity; active substances for the treatment of high blood pressure; active substances for the treatment of hyperlipidaemia, including arteriosclerosis; active substances for the treatment of dyslipidaemia, including arteriosclerosis; or active substances for the treatment of arthritis. 
     
     
         9 . The method according to claim  13 , comprising administering a second active ingredient comprising orlistat, phenetermine, sibutramine, or topiramate, or a pharmaceutically acceptable salt thereof. 
     
     
         10 . The method according to claim  13 , comprising administering a second active ingredient comprising ergoset, pramlintinide, leptin, BAY-27-9955, glipazide, glyburide, alprostadil, thipride hydrochloride, cilostazol, mexiletine hydrochloride, ethyl eicosapentate, memantine, or pimagedine, or a pharmaceutically acceptable salt thereof. 
     
     
         11 . The method according to claim  13 , comprising administering a second active ingredient comprising an insulin sensitiser, insulin secretion accelerator, biguanide, insulin, α-glucosidase inhibitor, or β3 adrenoreceptor agonist, glycogen phosphorylase inhibitor, sorbitol dyhydrogenase inhibitor, protein tyrosine phosphatase 1B inhibitor, dipeptidyl protease inhibitor, aldose reductase inhibitor, glycation inhibitor, protein kinase C inhibitor, DPPIV blocker, GLP-1 or GLP-2 analogue, or SGLT-2 inhibitor, lipase inhibitor, anorectic, angiotensin converting enzyme inhibitor, calcium antagonist, potassium channel opener, angiotensin II antagonist, HMG-CoA reductase inhibitor, fibrate compound, or non-steroidal anti-inflammatory drug. 
     
     
         12 . The method according to claim  13 , comprising administering a second active ingredient comprising pioglitazone or a pharmaceutically acceptable salt thereof, troglitazone, rosiglitazone or a pharmaceutically acceptable salt thereof, JTT-501, GI-262570, MCC-555, YM-440, DRF-2593, BM-13-1258, KRP-297, R-119702, GW-1929, tolbutamide, chloropropamide, tolazamide, acetohexamide, glyclopyramide, an ammonium salt of glyclopyramide, glibenclamide, gliclazide, glimepiride, repaglinide, nateglinide, mitiglinide, JTT-608, metformin, buformin, phenformin, bovine insulin, porcine insulin, semisynthetic human insulin, genetically-engineered human insulin, acarbose, voglibose, miglitol, emiglitate, AJ-9677, BMS-196085, SB-226552, AZ40140, tolrestat, epalrestat, imirestat, zenarestat, SNK-860, zopolrestat, ARI-50i, AS-3201, NGF, LY-333531, LAF237, MK431, 815541, 823093, 825964, liraglutide, exenatide, AVE-2268, T-1095, mazindol, baiamine, NGD-95-1, lipstatin, rimonabant, phenylpropanolamine, ephedrine, pseudroephedrine, dexfenfluramine, fenfluramine, BVT.933, APD356, bromocriptine, pramipexol, dehydroepiandrosterone, exendin, AC 2993, CJC-1131, ZP10, GRT0203Y, captopril, enalapril, alacepril, delapril, lisinopril, imidapril, benazepril, cilazapril, temocapril, trandolapril, manidipine, nifedipine, amlodipine, efonidipine, nicardipine, levcromakalim, L-27152, AL0671, NIP-121, telmisartan, losartan, candesartan cilexetil, valsartan, irbesartan, CS-866, E4177, pravastatin or a pharmaceutically acceptable salt thereof, simvastatin or a pharmaceutically acceptable salt thereof, lovastatin or a pharmaceutically acceptable salt thereof, atorvastatin or a pharmaceutically acceptable salt thereof, fluvastatin or a pharmaceutically acceptable salt thereof, lipantil or a pharmaceutically acceptable salt thereof, cerivastatin or a pharmaceutically acceptable salt thereof, itavastatin or a pharmaceutically acceptable salt thereof, ZD-4522 or a pharmaceutically acceptable salt thereof, bezafibrate, clinofibrate, clofibrate, simfibrate, meloxicam, ibuprofen, or mixtures thereof.